Found: 133
Select item for more details and to access through your institution.
Serum potassium variability as a predictor of clinical outcomes in patients with cardiorenal disease or diabetes: a retrospective UK database study.
- Published in:
- Clinical Kidney Journal, 2022, v. 15, n. 4, p. 758, doi. 10.1093/ckj/sfab225
- By:
- Publication type:
- Article
Comparative Growth and Development of Hexaploid and Tetraploid Reed Canarygrass.
- Published in:
- Crop Science, 2014, v. 54, n. 3, p. 1062, doi. 10.2135/cropsci2013.07.0430
- By:
- Publication type:
- Article
Yield and Yield Components of Winter-Type Safflower.
- Published in:
- Crop Science, 2012, v. 52, n. 5, p. 2358, doi. 10.2135/cropsci2011.12.0659
- By:
- Publication type:
- Article
Modeling the relationship between wolf control and cattle depredation.
- Published in:
- PLoS ONE, 2017, v. 12, n. 10, p. 1, doi. 10.1371/journal.pone.0187264
- By:
- Publication type:
- Article
Coordination of Leaf Photosynthesis, Transpiration, and Structural Traits in Rice and Wild Relatives (Genus Oryza).
- Published in:
- Plant Physiology, 2013, v. 162, n. 3, p. 1632, doi. 10.1104/pp.113.217497
- By:
- Publication type:
- Article
Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
- Published in:
- 2002
- By:
- Publication type:
- journal article
SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review.
- Published in:
- Diabetes Therapy, 2024, v. 15, n. 5, p. 1099, doi. 10.1007/s13300-024-01550-5
- By:
- Publication type:
- Article
Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK.
- Published in:
- Diabetes Therapy, 2023, v. 14, n. 6, p. 1005, doi. 10.1007/s13300-023-01408-2
- By:
- Publication type:
- Article
An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal–Bolus Insulin in Type 2 Diabetes.
- Published in:
- Diabetes Therapy, 2023, v. 14, n. 1, p. 123, doi. 10.1007/s13300-022-01344-7
- By:
- Publication type:
- Article
Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 5, p. 889, doi. 10.1007/s13300-022-01242-y
- By:
- Publication type:
- Article
The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 5, p. 847, doi. 10.1007/s13300-022-01228-w
- By:
- Publication type:
- Article
Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 2, p. 241, doi. 10.1007/s13300-022-01204-4
- By:
- Publication type:
- Article
Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 2, p. 225, doi. 10.1007/s13300-021-01201-z
- By:
- Publication type:
- Article
The Value of Insulin Degludec in Frail Older Adults with Type 2 Diabetes.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 11, p. 2817, doi. 10.1007/s13300-021-01162-3
- By:
- Publication type:
- Article
One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 6, p. 1593, doi. 10.1007/s13300-021-01061-7
- By:
- Publication type:
- Article
Correction to: Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Risk Prediction of the Diabetes Missing Million: Identifying Individuals at High Risk of Diabetes and Related Complications.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 1, p. 87, doi. 10.1007/s13300-020-00963-2
- By:
- Publication type:
- Article
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 1, p. 55, doi. 10.1007/s13300-020-00951-6
- By:
- Publication type:
- Article
SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 12, p. 2757, doi. 10.1007/s13300-020-00930-x
- By:
- Publication type:
- Article
Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 10, p. 2221, doi. 10.1007/s13300-020-00917-8
- By:
- Publication type:
- Article
Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 10, p. 2207, doi. 10.1007/s13300-020-00911-0
- By:
- Publication type:
- Article
Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 9, p. 1925, doi. 10.1007/s13300-020-00889-9
- By:
- Publication type:
- Article
Diabetes and Novel Coronavirus Infection: Implications for Treatment.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 9, p. 1915, doi. 10.1007/s13300-020-00858-2
- By:
- Publication type:
- Article
What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 6, p. 1381, doi. 10.1007/s13300-020-00834-w
- By:
- Publication type:
- Article
Drug Therapy in Obesity: A Review of Current and Emerging Treatments.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 6, p. 1199, doi. 10.1007/s13300-020-00816-y
- By:
- Publication type:
- Article
Correction to: Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 2, p. 369, doi. 10.1007/s13300-019-00747-3
- By:
- Publication type:
- Article
Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 1, p. 37, doi. 10.1007/s13300-019-00728-6
- By:
- Publication type:
- Article
Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin.
- Published in:
- Diabetes Therapy, 2019, v. 10, n. 5, p. 1793, doi. 10.1007/s13300-019-00685-0
- By:
- Publication type:
- Article
What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?
- Published in:
- Diabetes Therapy, 2019, v. 10, n. 5, p. 1719, doi. 10.1007/s13300-019-00678-z
- By:
- Publication type:
- Article
Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice.
- Published in:
- 2019
- By:
- Publication type:
- Correction Notice
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice.
- Published in:
- Diabetes Therapy, 2019, v. 10, n. 5, p. 1595, doi. 10.1007/s13300-019-0657-8
- By:
- Publication type:
- Article
A Summary of 2018 and What Lies Ahead for Diabetes Therapy in 2019.
- Published in:
- Diabetes Therapy, 2019, v. 10, n. 1, p. 1, doi. 10.1007/s13300-018-0559-1
- By:
- Publication type:
- Article
Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice’.
- Published in:
- Diabetes Therapy, 2018, v. 9, n. 5, p. 1729, doi. 10.1007/s13300-018-0494-1
- By:
- Publication type:
- Article
Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting.
- Published in:
- Diabetes Therapy, 2018, v. 9, n. 5, p. 1919, doi. 10.1007/s13300-018-0478-1
- By:
- Publication type:
- Article
SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice.
- Published in:
- Diabetes Therapy, 2018, v. 9, n. 5, p. 1757, doi. 10.1007/s13300-018-0471-8
- By:
- Publication type:
- Article
Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus.
- Published in:
- Diabetes Therapy, 2018, v. 9, n. 1, p. 27, doi. 10.1007/s13300-017-0329-5
- By:
- Publication type:
- Article
Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK.
- Published in:
- Diabetes Therapy, 2017, v. 8, n. 5, p. 1175, doi. 10.1007/s13300-017-0312-1
- By:
- Publication type:
- Article
Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus.
- Published in:
- Diabetes Therapy, 2017, v. 8, n. 2, p. 275, doi. 10.1007/s13300-017-0236-9
- By:
- Publication type:
- Article
Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective.
- Published in:
- Diabetes Therapy, 2016, v. 7, n. 4, p. 809, doi. 10.1007/s13300-016-0195-6
- By:
- Publication type:
- Article
Practical Approaches to Diabetes Care: An Introduction.
- Published in:
- Diabetes Therapy, 2016, v. 7, n. 3, p. 377, doi. 10.1007/s13300-016-0186-7
- By:
- Publication type:
- Article
Factors Predictive of Weight Gain and Implications for Modeling in Type 2 Diabetes Patients Initiating Metformin and Sulfonylurea Combination Therapy.
- Published in:
- Diabetes Therapy, 2015, v. 6, n. 4, p. 495, doi. 10.1007/s13300-015-0134-y
- By:
- Publication type:
- Article
Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?
- Published in:
- Diabetes Therapy, 2015, v. 6, n. 1, p. 1, doi. 10.1007/s13300-015-0104-4
- By:
- Publication type:
- Article
Increased Risk of Severe Hypoglycemic Events with Increasing Frequency of Non-severe Hypoglycemic Events in Patients with Type 1 and Type 2 Diabetes.
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 447, doi. 10.1007/s13300-014-0075-x
- By:
- Publication type:
- Article
Evaluation of Insulin Use and Value for Money in Type 2 Diabetes in the United Kingdom.
- Published in:
- Diabetes Therapy, 2013, v. 4, n. 1, p. 51, doi. 10.1007/s13300-012-0018-3
- By:
- Publication type:
- Article
A Retrospective, Case-Note Survey of Type 2 Diabetes Patients Prescribed Incretin-Based Therapies in Clinical Practice.
- Published in:
- Diabetes Therapy, 2013, v. 4, n. 1, p. 27, doi. 10.1007/s13300-012-0015-6
- By:
- Publication type:
- Article
Pioglitazone in Clinical Practice: Where Are We Now?
- Published in:
- Diabetes Therapy, 2012, v. 3, n. 1, p. 1, doi. 10.1007/s13300-012-0001-z
- By:
- Publication type:
- Article
Letter from the Editor.
- Published in:
- 2010
- By:
- Publication type:
- Letter
High-fat dairy product consumption increases Δ9 c’ 11 t−18∶2 (rumenic acid) and total lipid concentrations of human milk.
- Published in:
- Lipids, 1999, v. 34, n. 6, p. 543, doi. 10.1007/s11745-999-0396-2
- By:
- Publication type:
- Article
Real‐world use and cost of health and social care services of 18,116 patients living with Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.072433
- By:
- Publication type:
- Article